世界のワクチン市場

Abstract

Global Vaccine Manufacturers Need to Scale up Operations in Emerging Countries to Solve Issues of Supply and Demand

Vaccine manufacturers from all over the world have been involved in a stalemate with governments regarding supply and demand. While governments are reluctant to ensure steady demand for vaccines unless the manufacturers can prove their ability to increase their supply, the latter are apprehensive about increasing production without a guarantee of sustained demand from the governments. Meanwhile, developing nations are increasingly demanding vaccines that are no longer included in the immunization schedules of developed countries. These vaccines will have to be provided at very low costs, which will not be feasible unless the demand can compensate for the low margins. Tier 1 participants will have to take the responsibility of supplying vaccines to emerging markets by leveraging their presence in developing and low-cost nations such as India and China. By expanding their manufacturing base in these countries, they can supply to both developed and developing markets. Manufacturers also benefit from the lucrative private markets, rising economic prowess, and increased awareness of vaccines in these regions.

This Frost & Sullivan analysis examines the global vaccines markets, segmenting it into North American, European, and Rest-of-World regions. This study discusses the prevailing market drivers and restraints as well as enables companies to align their positioning strategies to benefit from the changing market conditions.

Strong Pipeline of Vaccines Hold Manufacturers in Good Stead in Developed Markets

Manufacturers that operate in saturated markets have to constantly launch new vaccines or improved versions with increased coverage and efficacy. Since the time to market for a vaccine is 12-14 years, it is vital for companies to have strong and well-developed product portfolios in the market as well as in the pipeline to ensure consistent growth.

Vaccine manufacturers, especially the top five, have robust pipelines. "There are at least 14 vaccines in phase III/registration phase that can ensure high growth with their inclusion in the national immunization programs across the United States and Europe," says the analyst of this study. "Two of these vaccines -- against Rotavirus and Human Papilomavirus (HPV) -- are likely to be the chief tools in building a strong foundation for growth of the vaccines market, which can be utilized by other products including the next-generation vaccines."

Regional Vaccine Manufacturers Take Advantage of Rising Costs to become Global Participants

Regional manufacturers have wrested the advantage from the major vaccine manufacturers that are pressured by rising costs and limited budgets for immunization programs. With the momentum shifting in their favor and providing them with a platform to expand their presence, regional participants have entered the global vaccines market. They have received ample financial support from the vaccine fund and other aid agencies for long-term funding of immunization programs.

Such backing has ensured consistent demand, which has, in turn, encouraged companies to supply large volumes of vaccines. "A large number of regional vaccine manufacturers have entered the market, thereby reducing cost and increasing supply," notes the analyst. "Eventually, these manufacturers can enter developed markets and expand their business into more profitable ventures."

Table of Contents

• 1. Executive Summary
  • 1. Executive Summary
    • 1. Executive Summary
• 2. Total Vaccines Markets
  • 1. Market Overview
    • 1. Introduction
    • 2. Market Engineering Measurements
    • 3. Market Segmentation
    • 4. Research Methodology
  • 2. SWOT Analysis and Revenue Forecasts
    • 1. SWOT Analysis
    • 2. Revenue Forecasts
  • 3. Market Challenges and Strategies
    • 1. Market Challenges
    • 2. Strategic Recommendations
  • 4. Frost and Sullivan Awards
    • 1. Growth Strategy Leadership of the Year Award
    • 2. Product Innovation of the Year Award
• 3. North American Vaccines Markets
  • 1. Market Overview
    • 1. Introduction
    • 2. Market Engineering Measurements
  • 2. Market Drivers Restraints and Trends
    • 1. Market Drivers
      • a. Positive Economic Impact of Vaccination Encourages Immunization Programs
      • b. Wider Media Coverage on Emerging Diseases and Increased Threat of Outbreaks Drives Vaccination Programs
      • c. Combination Vaccines Reduce Number of Physician Visits and Risk of Missed Shots and Encourages Vaccination
      • d. Launch of New Rotavirus and HPV Vaccines likely to Drive Growth of Market
      • e. Novel Delivery Platforms and Technologies Encourage Usage of Vaccines
    • 2. Market Restraints
      • a. High Barriers to Entry of New Vaccine Manufacturers Restrains Growth
      • b. High Cost of Clinical Trials for Already Existing Vaccines Discourages Introduction in U.S
      • c. Anti-Vaccination and Misinformation Groups Create Negative Image for Vaccines
      • d. Imbalance Between Vaccine Manufacturing Costs and Selling Prices Creates Fragility in Vaccine Supply
      • e. Success of Immunization Programs Creates Problems for Physicians and Patients
    • 3. Market Trends
  • 3. Revenue Forecast and Competitive Structure
    • 1. Revenue Forecasts
    • 2. Competitive Structure
• 4. European Vaccines Markets
  • 1. Market Overview
    • 1. Introduction
    • 2. Market Engineering Measurements
  • 2. Market Drivers Restraints and Trends
    • 1. Market Drivers
      • a. Strong Local Presence of Leading Vaccine Manufacturers Drives Growth
      • b. Huge Unmet Medical Need in Non-Pediatric Segment Presents Opportunity for Market Expansion
      • c. Launch of Human Papilomavirus Virus and Rotavirus Vaccine Drives Market Expansion
      • d. Expanded Use of Prevnar and Launch of Streptorix Propels Usage and Drives Expansion
      • e. Threat of Flu Pandemic drives Demand for Flu Vaccines
    • 2. Market Restraints
      • a. Highly Fragmented and Heterogeneous Local Markets Creates Barriers for Vaccine Manufacturers
      • b. Price Caps on Vaccines Lowers Margins for Manufacturers
      • c. Increasing Cost of Manufacturing and Clinical Trials Restrains Expansion Activities
    • 3. Market Trends
  • 3. Revenue Forecast and Competitive Structure
    • 1. Revenue Forecasts
    • 2. Competitive Structure
• 5. Rest-of-World Vaccines Markets
  • 1. Market Overview
    • 1. Introduction
    • 2. Market Engineering Measurements
  • 2. Market Drivers Restraints Trends
    • 1. Market Drivers
      • a. Huge Population Base offers Immense Growth Potential
      • b. Increasing Private-Public Partnerships Encourage Immunization Programs
      • c. Rising Economic Prowess of Developing Countries Encourages Healthcare Initiatives
      • d. High Birth Rates Ensure Consistent Demand for Pediatric Vaccines
    • 2. Market Restraints
      • a. Delivery of Vaccines in the Absence of a Structured Healthcare System is likely to Restrain Growth
      • b. Limited Public Awareness Among the Illiterate Curbs Immunization Programs
      • c. The Lack of Infrastructure to Handle Storage and Supply of Vaccines Deters Growth
      • d. Rising Manufacturing Costs Coupled with Limited Resources Creates Cost Pressures for Manufacturers
    • 3. Market Trends
  • 3. Revenue Forecast and Competitive Structure
    • 1. Revenue Forecasts
    • 2. Competitive Structure
• 6. Decision Support Databases
  • 1. Global Disease Profile
    • 1. Diphtheria Incidences
    • 2. Haemophilius Influenza B Incidences
    • 3. Hepatitis B Incidences
    • 4. Measles Incidences
    • 5. Mumps Incidences
    • 6. Rubella Incidences
    • 7. Pertussis Incidences

List of Figures

Chapter 2

• Vaccines Market: SWOT Analysis (World), 2006-2012
• Vaccines Market: Revenue Forecasts (World), 2002-2012
• Vaccines Market: Market Share Trends of Major Market Participants (World), 2002-2005
• Vaccines Market: Percent of Revenues by Geographic Region (World), 2002-2012
• Vaccines Market: Impact of Top Industry Challenges (World), 2006-2012
• Vaccines Market: Challenges and Corresponding Strategies (World), 2006-2012

Chapter 3

• Vaccines Market: Market Drivers Ranked in Order of Impact (North America), 2006-2012
• Vaccines Market: Market Restraints Ranked in Order of Impact (North America), 2006-2012
• Vaccines Market: Revenue Forecasts (North America), 2002-2012
• Vaccines Market: Competitive Structure (North America), 2005

Chapter 4

• Vaccines Market: Market Drivers Ranked in Order of Impact (Europe), 2006-2012
• Vaccines Market: Market Restraints Ranked in Order of Impact (Europe), 2006-2012
• Vaccines Market: Revenue Forecasts (Europe), 2002-2012
• Vaccines Market: Competitive Structure (Europe), 2005

Chapter 5

• Vaccines Market: Market Drivers Ranked in Order of Impact (Rest-of-World), 2006-2012
• Vaccines Market: Market Restraints Ranked in Order of Impact (Rest-of-World), 2006-2012
• Vaccines Market: Revenue Forecasts (Rest-of-World), 2002-2012
• Vaccines Market: Competitive Structure (Rest-of-World), 2005